EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

Pascale Tomasini iD, Yongsheng Wang, Yongsheng Li, Enriqueta Felip iD, Lin Wu iD, Jiuwei Cui, Benjamin Besse iD, Alexander I Spira iD, Joel W Neal iD, Koichi Goto iD, Christina S Baik, Melina E Marmarelis iD und 21 weitere

Journal of Clinical Oncology · 2026-01 · 44 (1) · 54-65

DOI: 10.1200/jco-24-02835 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2026-01. Verfasst von Pascale Tomasini und 32 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University - CNRS, INSERM, CRCM; CEPCM - AP-HM Hôpital de La Timone, Marseille, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE For patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor ( EGFR ) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment options is limited. PATIENTS AND METHODS CHRYSALIS-2 Cohort C enrolled participants with NSCLC harboring atypical EGFR mutations (G719X, S768I, L861Q, etc) and ≤2 previous lines of therapy. Participants were treatment-naïve or previously received first- or second-generation EGFR tyrosine kinase inhibitors. Coexisting exon 20 insertions, exon 19 deletions, or exon 21 L858R mutations were exclusionary. Participants received 1,050 mg (1,400 mg if ≥80 kg) intravenous amivantamab once weekly for the first 4 weeks and then once every 2 weeks plus 240 mg oral lazertinib once daily. The primary end point was investigator-assessed objective response rate (ORR). RESULTS As of January 12, 2024, 105 participants received amivantamab-lazertinib. Most common atypical mutations were G719X (56%), L861X (26%), and S768I (23%), including single and compound mutations. In the overall population (median follow-up: 16.1 months), the ORR was 52% (95% CI, 42 to 62). The median duration of response (mDoR) was 14.1 months (95% CI, 9.5 to 26.2). The median progression-free survival (mPFS) was 11.1 months (95% CI, 7.8 to 17.8); median overall survival (mOS) was not estimable (NE; 95% CI, 22.8 to NE). Adverse events were consistent with previous studies and primarily grade 1 and 2. Among treatment-naïve participants, the ORR was 57% (95% CI, 42 to 71). The mPFS was 19.5 months (95% CI, 11.2 to NE), the mDoR was 20.7 months (95% CI, 9.9 to NE), and mOS was NE (95% CI, 26.3 to NE). Solitary or compound EGFR mutations had no major impact on ORR. The ORR in participants with P-loop and αC-helix compressing, classical-like, and T790M-like mutations was 45% (n = 38), 64% (n = 14), and 67% (n = 3), respectively. CONCLUSION In participants with atypical EGFR -mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationAntineoplastic Combined Chemotherapy ProtocolsQuinolinesHumansFemaleMaleMiddle AgedAgedErbB ReceptorsAdultAged, 80 and overProtein Kinase InhibitorsAntibodies, Bispecific

Substanzen

ErbB ReceptorsEGFR protein, humanamivantamabQuinolinesProtein Kinase InhibitorsAntibodies, Bispecific

Autor:innen und Institutionen

  • Aix Marseille University - CNRS, INSERM, CRCM; CEPCM - AP-HM Hôpital de La Timone, Marseille, France.
  • Division of Thoracic Tumor Multimodality Treatment, Cancer Center and Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, China.
  • Chongqing University Cancer Hospital, Chongqing, China.
  • Medical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • The First Hospital of Jilin University, Changchun, China.

ORCID-Profile: Pascale Tomasini, Enriqueta Felip, Lin Wu, Benjamin Besse, Alexander I Spira, Joel W Neal, Koichi Goto, Melina E Marmarelis, Eiki Ichihara, James Chih-Hsin Yang, Sebastian Michels, Zacharias Anastasiou, Janine Mahoney, Craig S Meyer, Mahadi Baig, Joshua M Bauml, Byoung Chul Cho

Zitieren

APA

Tomasini, P., Wang, Y., Li, Y., Felip, E., Wu, L., Cui, J., Besse, B., Spira, A. I., Neal, J. W., Goto, K., Baik, C. S., Marmarelis, M. E., Ichihara, E., Zhang, Y., Lee, J. S., Lee, S. H., Yang, J. C., Michels, S., Anastasiou, Z., …, & CHRYSALIS-2 Cohort C (2026). Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2. Journal of Clinical Oncology, 44(1), 54-65. https://doi.org/10.1200/jco-24-02835

Vancouver

Tomasini P, Wang Y, Li Y, Felip E, Wu L, Cui J, et al. Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2. Journal of Clinical Oncology. 2026;44(1):54-65. doi:10.1200/jco-24-02835

BibTeX
@article{Tomasini2026,
  author = {Tomasini, Pascale and Wang, Yongsheng and Li, Yongsheng and Felip, Enriqueta and Wu, Lin and Cui, Jiuwei and Besse, Benjamin and Spira, Alexander I and Neal, Joel W and Goto, Koichi and Baik, Christina S and Marmarelis, Melina E and Ichihara, Eiki and Zhang, Yiping and Lee, Jong-Seok and Lee, Se-Hoon and Yang, James Chih-Hsin and Michels, Sebastian and Anastasiou, Zacharias and Curtin, Joshua C and Lyu, Xuesong and Mahoney, Janine and Demirdjian, Levon and Meyer, Craig S and Zhang, Youyi and Leconte, Isabelle and Lorenzini, Patricia and Knoblauch, Roland E and Trani, Leonardo and Baig, Mahadi and Bauml, Joshua M and Cho, Byoung Chul and CHRYSALIS-2 Cohort C, CHRYSALIS-2 Cohort C},
  title = {Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {1},
  pages = {54--65},
  doi = {10.1200/jco-24-02835}
}
Kostenlos starten →